Related content

Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA

By Ullenhag Gustav   Fagerberg Jan   Strigård Karin   Frödin Jan-Erik   Mellstedt Håkan  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 4, 2004-04 ,pp. : 331-337

Springer Publishing Company

Access to resources Recommend Favorite

Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine

By Cohen L.   de Moor C.   Parker P.A.   Amato R.J.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 3, 2002-05 ,pp. : 119-124

Elsevier

Access to resources Recommend Favorite

Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody

By Mayer A.   Chester K.A.   Bhatia J.   Pedley R.B.   Read D.A.   Boxer G.M.   Begent R.H.J.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 968-976

Elsevier

Access to resources Recommend Favorite

CEA, MCA, CA 15.3 and CA 549 and Their Combinations in Expressing and Monitoring Metastatic Breast Cancer: a Prospective Comparative Study

By Martoni A.   Zamagni C.   Bellanova B.   Zanichelli L.   Vecchi F.   Cacciari N.   Strocchi E.   Pannuti F.  

European Journal of Cancer, Vol. 31, Iss. 10, 1995-09 ,pp. : 1615-1621

Elsevier

Access to resources Recommend Favorite

Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer

By              

Experimental and Therapeutic Medicine, Vol. 2, Iss. 1, 2011-01 ,pp. : 73-79

Spandidos Publications

Access to resources Recommend Favorite